Evidence map›Paper›PMID 41987775›Full record

ArticleFrontiers in medicine2026

Fecal AAV8 shedding and co-housing reduces EAE disease severity: implications for preclinical study design.

Cristina D Gaddie, Geoffrey D Keeler

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Cristina D GaddieDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, United States.
Geoffrey D KeelerDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, United States.

Funding

Restoring Immune Tolerance in a Model of Multiple SclerosisR01AI128074 · NIAID · UNIVERSITY OF FLORIDA · PI Geoffrey D Keeler · 2017 to 2026
$3.7M
NIAID NIH HHS R01 AI128074
6 · The paper itself

Abstract

Adeno-Associated virus (AAV) vectors have become an invaluable tool in research and the clinic. Likewise, AAV is used in various animal models for investigating a host of diseases. However, AAV shedding, or the release of AAV particles from the body, remains an understudied field which could be detrimental to researchers and be a potential contributor to pre-clinical variability. To our knowledge, no studies have been performed to evaluate any relationship between AAV shed particles and the effects these particles may have on cage mates. As such, we evaluated the level of AAV viral genomes in the fecal matter of C57BL6/J mice following the intravenous administration of AAV8. Here we show that AAV genomes are shed from female C57BL/6J mice for a minimum of 2 months following intravenously injected AAV8 vector. We also sought to determine if these shed AAV particles could affect non-vectored cage mates in experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). We found an association between caging vectored animals with non-vectored animals and a reduction in disease severity in the non-vectored animals. We also found an association between disease severity and the ratio of vectored:non-vectored animals in the cage. Our findings should act as a word of caution to researchers performing AAV studies and should be considered to prevent confounding variables and bias in results.

Indexed as

AAV sheddingAAV viral genomesexperimental autoimmune encephalomyelitismultiple sclerosispre-clinical variability

Identifiers

PMID41987775
PMCPMC13076483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.